To include your compound in the COVID-19 Resource Center, submit it here.

Management tracks: Allogene snags Adaptimmune's Amado; plus Foundation Medicine, CymaBay and more

CAR T therapy company Allogene Therapeutics Inc. (NASDAQ:ALLO) hired Rafael G. Amado as EVP of R&D and CMO, effective

Read the full 196 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE